BIOMAT Database Logo BIOMAT Database Logo

Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. 2003

Ulrik Bak Dragsted, and Jan Gerstoft, and Court Pedersen, and Barry Peters, and Adriana Duran, and Niels Obel, and Antonella Castagna, and Pedro Cahn, and Nathan Clumeck, and Johan N Bruun, and Jorge Benetucci, and Andrew Hill, and Isabel Cassetti, and Pietro Vernazza, and Mike Youle, and Zoe Fox, and Jens D Lundgren, and
Hvidovre University Hospital, Hvidovre, Denmark. ubd@cphiv.dk

This trial assessed the rate of virological failure at 48 weeks in adult human immunodeficiency virus (HIV) type 1-infected patients assigned indinavir/ritonavir (Idv/Rtv; 800/100 mg 2 times daily) or saquinavir/ritonavir (Sqv/Rtv; 1000/100 mg 2 times daily) in an open-label, randomized (1:1), multicenter, phase 4 design. Three hundred six patients began the assigned treatment. At 48 weeks, virological failure was seen in 43 (27%) of 158 and 37 (25%) of 148 patients in the Idv/Rtv and Sqv/Rtv arms, respectively. The time to virological failure did not differ between study arms (P=.76). When switching from randomized treatment was counted as failure, this was seen in 78 of 158 patients in the Idv/Rtv arm, versus 51 of 148 patients in the Sqv/Rtv arm (P=.009). A switch from the randomized treatment occurred in 64 (41%) of 158 patients in the Idv/Rtv arm, versus 40 (27%) of 148 patients in the Sqv/Rtv arm (P=.013). Sixty-four percent of the switches occurred because of adverse events. A greater number of treatment-limiting adverse events were observed in the Idv/Rtv arm, relative to the Sqv/Rtv arm. In conclusion, Rtv-boosed Sqv and Idv were found to have comparable antiretroviral effects in the doses studied.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D019258 Saquinavir An HIV protease inhibitor which acts as an analog of an HIV protease cleavage site. It is a highly specific inhibitor of HIV-1 and HIV-2 proteases, and also inhibits CYTOCHROME P-450 CYP3A. Invirase,Ro 31-8959,Saquinavir Mesylate,Saquinavir Monomethanesulfonate,Saquinivir,Monomethanesulfonate, Saquinavir,Ro 31 8959,Ro 318959
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV

Related Publications

Ulrik Bak Dragsted, and Jan Gerstoft, and Court Pedersen, and Barry Peters, and Adriana Duran, and Niels Obel, and Antonella Castagna, and Pedro Cahn, and Nathan Clumeck, and Johan N Bruun, and Jorge Benetucci, and Andrew Hill, and Isabel Cassetti, and Pietro Vernazza, and Mike Youle, and Zoe Fox, and Jens D Lundgren, and
Ritonavir-saquinavir dual protease inhibitor compared to ritonavir alone in human immunodeficiency virus-infected patients.
December 2001, Antimicrobial agents and chemotherapy,
Ulrik Bak Dragsted, and Jan Gerstoft, and Court Pedersen, and Barry Peters, and Adriana Duran, and Niels Obel, and Antonella Castagna, and Pedro Cahn, and Nathan Clumeck, and Johan N Bruun, and Jorge Benetucci, and Andrew Hill, and Isabel Cassetti, and Pietro Vernazza, and Mike Youle, and Zoe Fox, and Jens D Lundgren, and
Comparison of P-triglyceride levels among patients with human immunodeficiency virus on randomized treatment with ritonavir, indinavir or ritonavir/saquinavir.
January 2001, Scandinavian journal of infectious diseases,
Ulrik Bak Dragsted, and Jan Gerstoft, and Court Pedersen, and Barry Peters, and Adriana Duran, and Niels Obel, and Antonella Castagna, and Pedro Cahn, and Nathan Clumeck, and Johan N Bruun, and Jorge Benetucci, and Andrew Hill, and Isabel Cassetti, and Pietro Vernazza, and Mike Youle, and Zoe Fox, and Jens D Lundgren, and
Prospective follow-up of 67 indinavir-experienced human immunodeficiency virus-infected and AIDS patients treated with the ritonavir/saquinavir combination.
May 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Ulrik Bak Dragsted, and Jan Gerstoft, and Court Pedersen, and Barry Peters, and Adriana Duran, and Niels Obel, and Antonella Castagna, and Pedro Cahn, and Nathan Clumeck, and Johan N Bruun, and Jorge Benetucci, and Andrew Hill, and Isabel Cassetti, and Pietro Vernazza, and Mike Youle, and Zoe Fox, and Jens D Lundgren, and
Pharmacokinetics of indinavir combined with low-dose ritonavir in human immunodeficiency virus type 1-infected children.
May 2004, Antimicrobial agents and chemotherapy,
Ulrik Bak Dragsted, and Jan Gerstoft, and Court Pedersen, and Barry Peters, and Adriana Duran, and Niels Obel, and Antonella Castagna, and Pedro Cahn, and Nathan Clumeck, and Johan N Bruun, and Jorge Benetucci, and Andrew Hill, and Isabel Cassetti, and Pietro Vernazza, and Mike Youle, and Zoe Fox, and Jens D Lundgren, and
[A randomized clinical trial to compare the effectiveness of indinavir, ritonavir and saquinavir].
October 2003, Medicina clinica,
Ulrik Bak Dragsted, and Jan Gerstoft, and Court Pedersen, and Barry Peters, and Adriana Duran, and Niels Obel, and Antonella Castagna, and Pedro Cahn, and Nathan Clumeck, and Johan N Bruun, and Jorge Benetucci, and Andrew Hill, and Isabel Cassetti, and Pietro Vernazza, and Mike Youle, and Zoe Fox, and Jens D Lundgren, and
Antagonism between human immunodeficiency virus type 1 protease inhibitors indinavir and saquinavir in vitro.
July 1997, The Journal of infectious diseases,
Ulrik Bak Dragsted, and Jan Gerstoft, and Court Pedersen, and Barry Peters, and Adriana Duran, and Niels Obel, and Antonella Castagna, and Pedro Cahn, and Nathan Clumeck, and Johan N Bruun, and Jorge Benetucci, and Andrew Hill, and Isabel Cassetti, and Pietro Vernazza, and Mike Youle, and Zoe Fox, and Jens D Lundgren, and
Drug monitoring and viral response to lopinavir/ritonavir or saquinavir/ritonavir containing regimens in individuals infected with the human immunodeficiency virus type 1.
January 2005, International journal of immunopathology and pharmacology,
Ulrik Bak Dragsted, and Jan Gerstoft, and Court Pedersen, and Barry Peters, and Adriana Duran, and Niels Obel, and Antonella Castagna, and Pedro Cahn, and Nathan Clumeck, and Johan N Bruun, and Jorge Benetucci, and Andrew Hill, and Isabel Cassetti, and Pietro Vernazza, and Mike Youle, and Zoe Fox, and Jens D Lundgren, and
Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir.
January 2001, Journal of virology,
Ulrik Bak Dragsted, and Jan Gerstoft, and Court Pedersen, and Barry Peters, and Adriana Duran, and Niels Obel, and Antonella Castagna, and Pedro Cahn, and Nathan Clumeck, and Johan N Bruun, and Jorge Benetucci, and Andrew Hill, and Isabel Cassetti, and Pietro Vernazza, and Mike Youle, and Zoe Fox, and Jens D Lundgren, and
Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children.
March 2001, Antimicrobial agents and chemotherapy,
Ulrik Bak Dragsted, and Jan Gerstoft, and Court Pedersen, and Barry Peters, and Adriana Duran, and Niels Obel, and Antonella Castagna, and Pedro Cahn, and Nathan Clumeck, and Johan N Bruun, and Jorge Benetucci, and Andrew Hill, and Isabel Cassetti, and Pietro Vernazza, and Mike Youle, and Zoe Fox, and Jens D Lundgren, and
Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women.
February 2004, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!